Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer ; volume:20 ; number:1 ; day:2 ; month:12 ; year:2019 ; pages:1-14 ; date:12.2019
Respiratory research ; 20, Heft 1 (2.12.2019), 1-14, 12.2019
- Urheber
-
Tong, Xuexia
Tanino, Ryosuke
Sun, Rong
Tsubata, Yukari
Okimoto, Tamio
Takechi, Mayumi
Isobe, Takeshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-019-1244-2
- URN
-
urn:nbn:de:101:1-2020032523163850718117
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tong, Xuexia
- Tanino, Ryosuke
- Sun, Rong
- Tsubata, Yukari
- Okimoto, Tamio
- Takechi, Mayumi
- Isobe, Takeshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
TKi | TKi
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
TKi | TKi
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
TKi | TKi
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung